Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC17637 CTX0294885 Pan-kinase inhibitor CTX0294885  Chemical Structure
  3. GC16008 CUDC-101 A multi-target inhibitor of HDACs, EGFR, and HER2 CUDC-101  Chemical Structure
  4. GC38180 Cyasterone Cyasterone  Chemical Structure
  5. GC13780 Cyclotraxin B TrkB receptor antagonist Cyclotraxin B  Chemical Structure
  6. GC16731 CZC 54252 hydrochloride CZC 54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC 54252 hydrochloride  Chemical Structure
  7. GC16038 CZC-25146 LRRK2 inhibitor CZC-25146  Chemical Structure
  8. GC35792 CZC-25146 hydrochloride CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride  Chemical Structure
  9. GC33351 CZC-8004 (CZC-00008004) CZC-8004 (CZC-00008004) (CZC-00008004), an aminopyrimidine, is a pan-kinase inhibitor. CZC-8004 (CZC-00008004) can bind a range of tyrosine kinases, including EGFR and VEGFR2 with IC50 values of 650 and 437 nM, respectively. CZC-8004 (CZC-00008004)  Chemical Structure
  10. GC43433 D-Glucosamine-6-sulfate D-Glucosamine-6-sulfate is a naturally occurring glycosaminoglycan. D-Glucosamine-6-sulfate  Chemical Structure
  11. GC62712 DA-JC4 DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways. DA-JC4  Chemical Structure
  12. GC10225 Dacomitinib (PF299804, PF299) Dacomitinib (PF299804, PF299) (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively. Dacomitinib (PF299804, PF299)  Chemical Structure
  13. GC15211 Damnacanthal p56lck tyrosine kinase inhibitor Damnacanthal  Chemical Structure
  14. GC15217 Danusertib (PHA-739358) A pan-Aurora kinase and Abl inhibitor Danusertib (PHA-739358)  Chemical Structure
  15. GN10336 Daphnetin Daphnetin  Chemical Structure
  16. GC15568 Dasatinib (BMS-354825) An inhibitor of Abl and Src Dasatinib (BMS-354825)  Chemical Structure
  17. GC35812 Dasatinib hydrochloride A potent and dual AblWT/Src inhibitor Dasatinib hydrochloride  Chemical Structure
  18. GC15884 Dasatinib Monohydrate Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. Dasatinib Monohydrate  Chemical Structure
  19. GC45687 Dasatinib N-oxide A major metabolite of dasatinib Dasatinib N-oxide  Chemical Structure
  20. GC62569 DBPR112 DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy. DBPR112  Chemical Structure
  21. GC14007 DCC-2036 (Rebastinib) DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit. DCC-2036 (Rebastinib)  Chemical Structure
  22. GC11171 DCC-2618 A dual inhibitor of c-Kit and c-MET DCC-2618  Chemical Structure
  23. GC33361 DDR Inhibitor DDR Inhibitor is a potent discoidin domain receptor (DDR) inhibitor, with an IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM. DDR Inhibitor  Chemical Structure
  24. GC17365 DDR1-IN-1 selective DDR1 receptor tyrosine kinase inhibitor DDR1-IN-1  Chemical Structure
  25. GC35822 DDR1-IN-1 dihydrochloride DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC50 of 105 nM; 4-fold less potent for DDR2 (IC50 = 413 nM). DDR1-IN-1 dihydrochloride  Chemical Structure
  26. GC31724 DDR1-IN-2 DDR1-IN-2 (DDR1-IN-2) is a potent inhibitor of discoidin domain receptor 1 (DDR1), with an IC50 of 13.1 nM, and also less potently inhibits DDR2, with an IC50 of 203 nM. DDR1-IN-2  Chemical Structure
  27. GC33297 DDR1-IN-3 DDR1-IN-3 is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC50 value of 9.4 nM. DDR1-IN-3 also inhibits TRK family. DDR1-IN-3  Chemical Structure
  28. GC64268 DDR1-IN-4 DDR1-IN-4 (Compound 2.45) is a selective and potent Discoidin Domain Receptor 1 (DDR1) autophosphorylation inhibitor, with IC50 values of 29 nM and 1.9 μM for DDR1 and DDR2, respectively. DDR1-IN-4  Chemical Structure
  29. GC65378 DDR1-IN-5 DDR1-IN-5 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 4.1 nM. DDR1-IN-5 has anti-cancer activity. DDR1-IN-5  Chemical Structure
  30. GC66476 DDR1-IN-6 DDR1-IN-6 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 9.7 nM. DDR1-IN-6 has anti-cancer activity. DDR1-IN-6  Chemical Structure
  31. GC16813 Defactinib

    FAK phosphorylation inhibitor

    Defactinib  Chemical Structure
  32. GC35827 Defactinib hydrochloride A novel FAK inhibitor Defactinib hydrochloride  Chemical Structure
  33. GC47182 Dehydrolithocholic Acid Dehydrolithocholic Acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM). Dehydrolithocholic Acid  Chemical Structure
  34. GC14905 Demethylasterriquinone B1

    An insulin receptor (IR) activator

    Demethylasterriquinone B1  Chemical Structure
  35. GC19399 Derazantinib Derazantinib (ARQ-087) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively. Derazantinib  Chemical Structure
  36. GC62107 DGY-06-116 DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM. DGY-06-116  Chemical Structure
  37. GC30768 Dihexa (PNB-0408)

    Dihexa (PNB-0408) (N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide) is an oral active, blood-brain barrier-permeable angiotensin IV analogue.

    Dihexa (PNB-0408)  Chemical Structure
  38. GC64039 Disitamab vedotin Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity. Disitamab vedotin  Chemical Structure
  39. GC14298 DMH-1 Selective BMP ALK2 receptor DMH-1  Chemical Structure
  40. GC17098 DMH4 VEGFR-2 inhibitor DMH4  Chemical Structure
  41. GC43503 DMHAPC-Chol DMHAPC-Chol is a cationic cholesterol. DMHAPC-Chol  Chemical Structure
  42. GC17024 DMPQ dihydrochloride PDGFRβ inhibitor DMPQ dihydrochloride  Chemical Structure
  43. GC10165 Dovitinib (TKI258) Lactate Dovitinib (TKI258) Lactate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib (TKI258) Lactate  Chemical Structure
  44. GC11372 Dovitinib Dilactic acid FLT3 inhibitor Dovitinib Dilactic acid  Chemical Structure
  45. GC32760 Dovitinib lactate (CHIR-258 lactate) Dovitinib lactate (CHIR-258 lactate) (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib lactate (CHIR-258 lactate)  Chemical Structure
  46. GC45767 Dovitinib-d8 An internal standard for the quantification of dovitinib Dovitinib-d8  Chemical Structure
  47. GC35897 DPH A potent cell permeable c-Abl activator DPH  Chemical Structure
  48. GC62597 DS-1205b free base DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo. DS-1205b free base  Chemical Structure
  49. GC62946 DYRK1-IN-1 DYRK1-IN-1 is a highly selective and ligand-efficient DYRK1A inhibitor. DYRK1-IN-1  Chemical Structure
  50. GC62947 DYRKs-IN-1 hydrochloride DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity. DYRKs-IN-1 hydrochloride  Chemical Structure
  51. GC12149 E-3810 E-3810  Chemical Structure
  52. GC62696 E7090 succinate E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively. E7090 succinate  Chemical Structure
  53. GC66432 EAI001 EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer. EAI001  Chemical Structure
  54. GC12281 EAI045 Inhibitor of L858R/T790M EGFR mutants EAI045  Chemical Structure
  55. GC64730 EB-42486 EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50 < 0.2 nM). EB-42486  Chemical Structure
  56. GC32825 eCF506 An inhibitor of Src kinases eCF506  Chemical Structure
  57. GC67879 Edecesertib Edecesertib  Chemical Structure
  58. GC19418 Edicotinib Edicotinib is a selective and orally available colony-stimulating factor-1 (CSF-1) receptor inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease. Edicotinib  Chemical Structure
  59. GC16183 EG00229

    Nrp1 inhibitor

    EG00229  Chemical Structure
  60. GC16321 EGF816 EGF816 (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min-1 on EGFR(L858R/790M) mutant, respectively. EGF816  Chemical Structure
  61. GC11312 EGFR Inhibitor EGFR Inhibitor is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective EGFR inhibitor with an IC50of 21 nM. EGFR Inhibitor also inhibits mutant EGFRL858R and EGFRL861Q with IC50s of 63 nM and 4 nM, respectively. EGFR Inhibitor displays strong selectivity for EGFR over HER4 (IC50 = 7640 nM) and a panel of 55 other kinases. EGFR Inhibitor induces cells apoptosis and has antitumor activity. EGFR Inhibitor  Chemical Structure
  62. GC35965 EGFR mutant-IN-1 EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective EGFRL858R/T790M/C797S mutant inhibitor with an IC50 of 27.5 nM, while being a significantly less potent for EGFRWT (IC50 >1.0 μM). EGFR mutant-IN-1  Chemical Structure
  63. GC65572 EGFR Protein Tyrosine Kinase Substrate EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate. EGFR Protein Tyrosine Kinase Substrate  Chemical Structure
  64. GC62562 EGFR-IN-11 EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC50 of 18 nM for triple mutant EGFRL858R/T790M/C797S. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1. EGFR-IN-11  Chemical Structure
  65. GC64497 EGFR-IN-17 EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance. EGFR-IN-17  Chemical Structure
  66. GC33195 EGFR-IN-2 EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor. EGFR-IN-2  Chemical Structure
  67. GC19132 EGFR-IN-3 EGFR-IN-3 is a third-generation EGFR TKI, with GI50 values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. EGFR-IN-3 has the potential for NSCLC research. EGFR-IN-3  Chemical Structure
  68. GC66428 EGFR-IN-5 EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively. EGFR-IN-5  Chemical Structure
  69. GC68440 EGFR-IN-69 EGFR-IN-69  Chemical Structure
  70. GC35966 EGFR-IN-7 EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 shows anti-tumor activity. EGFR-IN-7 can be used for the research of various cancers. EGFR-IN-7  Chemical Structure
  71. GC65974 EGFR-IN-9 EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity. EGFR-IN-9  Chemical Structure
  72. GC14856 EGFR/ErbB2 Inhibitor EGFR/ErbB2 Inhibitor (Compound 5) is a EGFR and ErbB inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM. EGFR/ErbB2 Inhibitor  Chemical Structure
  73. GC25367 Ehp-inhibitor-1 Ehp-inhibitor-1 (Ehp inhibitor 2) is an Eph family tyrosine kinase inhibitor that targets Eph receptors. Ehp-inhibitor-1  Chemical Structure
  74. GC38330 EHT 5372 EHT 5372  Chemical Structure
  75. GC10466 EMD-1214063

    EMD-1214063 (Tepotinib, MSC2156119J) is a novel potent and highly selective reversible, ATP-competitive small molecule c-Met inhibitor .

    EMD-1214063  Chemical Structure
  76. GC60805 EMI48 EMI48, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI48 inhibits EGFR triple mutants. EMI48  Chemical Structure
  77. GC62420 EMI56 EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants. EMI56  Chemical Structure
  78. GC65354 Enbezotinib Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer. Enbezotinib  Chemical Structure
  79. GC16519 ENMD-2076 A multi-kinase inhibitor ENMD-2076  Chemical Structure
  80. GC12145 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid  Chemical Structure
  81. GC33190 Ensartinib (X-396) Ensartinib (X-396) (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib (X-396)  Chemical Structure
  82. GC32864 Ensartinib hydrochloride (X-396 hydrochloride) Ensartinib hydrochloride (X-396 hydrochloride) (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. Ensartinib hydrochloride (X-396 hydrochloride)  Chemical Structure
  83. GC38776 Ensulizole Ensulizole is a sulfonated UV absorber and can intense UVB and partial UVA absorption. Ensulizole  Chemical Structure
  84. GC14476 Entrectinib Orally active inhibitor of ALK kinase Entrectinib  Chemical Structure
  85. GC65380 Envonalkib Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer. Envonalkib  Chemical Structure
  86. GC33048 Epertinib (S-22611) Epertinib (S-22611) (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib (S-22611) shows potent antitumor activity. Epertinib (S-22611)  Chemical Structure
  87. GC38350 Epertinib hydrochloride Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity. Epertinib hydrochloride  Chemical Structure
  88. GC62384 Epitinib succinate Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer. Epitinib succinate  Chemical Structure
  89. GC63390 EPQpYEEIPIYL EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains. EPQpYEEIPIYL  Chemical Structure
  90. GC12958 ER 27319 maleate Selective inhibitor of Syk kinase ER 27319 maleate  Chemical Structure
  91. GC52516 Erbstatin A tyrosine kinase inhibitor Erbstatin  Chemical Structure
  92. GC19142 Erdafitinib A pan-FGFR tyrosine kinase inhibitor Erdafitinib  Chemical Structure
  93. GC10627 Erlotinib An EGFR tyrosine kinase inhibitor Erlotinib  Chemical Structure
  94. GC60154 Erlotinib D6 Erlotinib D6 (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6  Chemical Structure
  95. GC15600 Erlotinib Hydrochloride An EGFR tyrosine kinase inhibitor Erlotinib Hydrochloride  Chemical Structure
  96. GC36003 Erlotinib mesylate EGFR inhibitor Erlotinib mesylate  Chemical Structure
  97. GC62958 Erlotinib-13C6 Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib-13C6  Chemical Structure
  98. GC47303 Erlotinib-d6 (hydrochloride) An internal standard for the quantification of erlotinib Erlotinib-d6 (hydrochloride)  Chemical Structure
  99. GC36021 F-1 F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively. F-1  Chemical Structure
  100. GC12174 FAK Inhibitor 14 FAK Inhibitor 14 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth. FAK Inhibitor 14  Chemical Structure
  101. GC36025 FAK inhibitor 2 FAK inhibitor 2 is a potent focal adhesion kinase (FAK) inhibitor with an IC50 ?of 0.07?nM, with antitumor and anti-angiogenesis activities. FAK inhibitor 2  Chemical Structure

Items 301 to 400 of 1115 total

per page
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6

Set Descending Direction